July 24, 2012 — Mevion Medical Systems announced today that it has delivered the superconducting synchrocyclotron for the Mevion S250 Proton Therapy System currently under installation at Robert Wood Johnson University Hospital in New Brunswick, N.J., the flagship cancer hospital of The Cancer Institute of New Jersey and the principle teaching hospital of UMDNJ-Robert Wood Johnson Medical School. This is the second Mevion S250 proton therapy system was delivered in the past six months, both installed at NCI-designated Comprehensive Cancer Centers.
Powered by a TriNiobium Core, the Mevion S250 is a modern and first-of-its-kind proton therapy system that provides the same precise, non-invasive treatment capabilities and advantages of complex, large and costly proton therapy systems but with a significantly reduced footprint, improved reliability, more advanced clinical systems, and lower implementation and operational costs.
The Mevion S250 has recently received United States Food and Drug Administration (FDA) 510(k) clearance and CE mark enabling Mevion customers to treat patients.
For more information: www.mevion.com
April 18, 2024 
